News

A glance at Johnson & Johnson 3rd-quarter sales by division and selected products, categories

A look at health care giant Johnson & Johnson’s third-quarter revenue by division and for selected products and categories:

CONSUMER HEALTH PRODUCTS 3Q 2013 3Q 2012 Change

U.S. Total $1.23 B $1.21 B up 0.9 per cent

International Total $2.39 B $2.37 B up 0.8 per cent

Worldwide Total $3.61 B $3.58 B up 0.8 per cent

Nonprescription drugs/nutritionals-U.S. $310 M $263 M up 17.9 per cent

PRESCRIPTION DRUGS 3Q 2013 3Q 2012 Change

U.S. Total $3.55 B $3.29 B up 7.9 per cent

International Total $3.49 B $3.11 B up 12 per cent

Worldwide Total $7.04 B $6.40 B up 9.9 per cent

Remicade (immune disorders) $1.69 B $1.59 B up 6.2 per cent

Stelara (psoriasis) $370 M $287 M up 29 per cent

Prezista (HIV) $410 M $364 M up 12.6 per cent

Concerta (attention deficit disorder) $142 M $254 M down 44 per cent

Invega Sustenna (schizophrenia) $324 M $212 M up 53 per cent

Zytiga (prostate cancer) $464 M $265 M up 75 per cent

Velcade (multiple myeloma) $404 M $327 M up 24 per cent

Procrit (anemia from cancer/dialysis) $344 M $359 M down 4.2 per cent

Xarelto (clot prevention) $246 M $68 M up 262 per cent

MEDICAL DEVICES & DIAGNOSTICS 3Q 2013 3Q 2012 Change

U.S. Total $3.15 B $3.29 B down 4.2 per cent

International Total $3.78 B $3.78 B down 0.1 per cent

Worldwide Total $6.93 B $7.07 B down 2 per cent

Diabetes Care-U.S. $237 M $328 M down 28 per cent

Diagnostic Tests/Equipment-Global $459 M $513 M down 10.5 per cent

Orthopedic Products-Global $2.28 B $2.29 B down 0.3 per cent

TOTAL SALES 3Q 2013 3Q 2012 Change

U.S. $7.93 B $7.79 B up 1.7 per cent

International $9.65 B $9.26 B up 4.2 per cent

Worldwide Total $17.58 B $17.05 B up 3.1 per cent

___

Source: Johnson & Johnson